Skip to main content
Timeline to first-in-child trials of FDA-approved cancer drugs examined

Researchers found that the median gap between first-in-human and first-in-child clinical trials for FDA-approved cancer drugs was 6.5 years. Of the 117 oncology drugs slated for final analysis by the FDA, 15 have yet to reach the first-in-children clinical trial stage, and five of those target acute lymphoblastic leukemia, according to the study in the European Journal of Cancer.

Full Story: